Search for other papers by Antonella Giampietro in
Google Scholar
PubMed
Search for other papers by Sabrina Chiloiro in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Martin Ove Carlsson in
Google Scholar
PubMed
Search for other papers by Francesca Dassie in
Google Scholar
PubMed
Search for other papers by Nunzia Prencipe in
Google Scholar
PubMed
Search for other papers by Marta Ragonese in
Google Scholar
PubMed
Search for other papers by Roy Gomez in
Google Scholar
PubMed
Search for other papers by Simona Granato in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavò in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Pietro Maffei in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
inconsistent between studies, and this topic is open to discussion. Thus, the aim of this analysis was to examine which factors are associated with the achievement of disease control using data from ACROSTUDY, a large international study of pegvisomant
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
, pegvisomant (PEG), is a second-line treatment which normalizes IGF-1 plasma levels in 60–70% ( 5 ) of patients in follow-up registries and up to 97% in single-center series ( 6 ). The dopamine D2-receptor agonist, cabergoline, is an alternative to 1 GSSA
Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Pegvisomant (4, 24) GHR antagonist 10–40 mg/day, SC 70 No effect Injection-site reactions, elevated liver enzymes GHR, growth hormone receptor; IM, intramuscular; SC, subcutaneous; SST, somatostatin receptor. Somatostatin
Search for other papers by Julie M Silverstein in
Google Scholar
PubMed
, there is no evidence of this association in patients with acromegaly who are treated with lower doses (38, 39) . As observed with SSAs, gastrointestinal discomfort is the AE most widely reported to be associated with cabergoline (40) . Pegvisomant is a
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin
Search for other papers by Cecilia Follin in
Google Scholar
PubMed
Search for other papers by Sven Karlsson in
Google Scholar
PubMed
remnant tissue and thus lead to reduced IGF-1 levels and reduced symptoms ( 6 , 7 ). A GH-receptor antagonist (e.g. pegvisomant) is also an option, and such drugs block the effects of GH at the level of the GH receptor and also reduce IGF-1 levels and
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
-generation somatostatin analogs in patients with AIP mutations, the role of other agents such as the GH receptor antagonist pegvisomant has been described in those with AIP mutations ( 14 ). Pasireotide is a newer somatostatin analog that is approved for use in
Search for other papers by Nelma Veronica Marques in
Google Scholar
PubMed
Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
/or cabergoline. Patients were not suitable for another surgical intervention because MRI did not show a clear residual lesion or showed a lesion that could not be resected. Pegvisomant is not available in the public health service in our country, and treatment
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
AJ Dimaraki EV Stewart PM Friend KE Vance ML , et al . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant . New England Journal of Medicine 2000 342 1171 – 1177 . ( https://doi.org/10.1056/NEJM200004203421604 ) 10
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by David A Cano in
Google Scholar
PubMed
Search for other papers by Eva Venegas-Moreno in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Elena Dios in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Alvaro Flores-Martínez in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Alfonso Soto-Moreno in
Google Scholar
PubMed
. Pituitary 2015 18 803 – 807 . ( https://doi.org/10.1007/s11102-015-0655-4 ) 25893613 10.1007/s11102-015-0655-4 4 Neggers SJCMM de Herder WW Feelders RA van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long